Restasis: Why US consumers paid billions for drug deemed ineffective in other countries

Jan. 4, 2018 – Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it’s not approved in the European Union, Australia or New Zealand? Restasis, a blockbuster drug sold by Allergan to treat chronic dry eye, has done $8.8 billion in U.S. sales […]

Advertisements